Posted by Michael Wonder on 02 May 2016
Are the days of big pharma dominating the agenda of a PBAC meeting over?
2 May 2016 - The sponsor with the most number of submissions on the agenda for the next PBAC meeting Gilead with five. This is the first time Gilead has lead the pack.
The PBAC will consider 47 submissions at its next scheduled meeting in July. The leading applicants are:
- Gilead - 5 submissions
- Novartis - 4 submissions
- Amgen - 4 submissions
- BMS - 3 submissions
For the past five years, the "big 12" (AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Eli Lilly, Janssen-Cilag, GSK, MSD, Novartis, Pfizer, Roche and Sanofi) has contributed over 40% of all submissions considered by the PBAC. Their combined contribution for the July meeting is just 30%. Four of the 12 have not lodged a submission for the July meeting.
On the flip side, there are 4 new sponsors:
- My Health 365
- Stada
- Stallergenes (first ever (minor) submission was considered at the March 2016 meeting)
- Daiichi Sankyo
